AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tubulin gamma-1 chain

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P23258

UPID:

TBG1_HUMAN

Alternative names:

Gamma-1-tubulin; Gamma-tubulin complex component 1

Alternative UPACC:

P23258; Q53X79; Q9BW59

Background:

The Tubulin gamma-1 chain, also known as Gamma-1-tubulin and Gamma-tubulin complex component 1, plays a pivotal role in cell division. It is a fundamental component of microtubules, crucial for forming the microtubule organizing centers (MTOC), including spindle poles and the centrosome. This protein is instrumental in regulating alpha/beta chain minus-end nucleation, centrosome duplication, and spindle formation, which are essential processes for cellular replication and health.

Therapeutic significance:

The Tubulin gamma-1 chain is linked to Cortical dysplasia, complex, with other brain malformations 4, a disorder characterized by early-onset seizures, microcephaly, and various cortical development malformations. Understanding the role of Tubulin gamma-1 chain could open doors to potential therapeutic strategies for this and related neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.